On April 20, 2026, NeOnc Technologies Holdings, Inc. entered into a Securities Purchase Agreement to sell up to 406,694 shares of common stock at $7.20 each, aiming to raise approximately $2 million for NEO216 preclinical trials. This filing is a significant event as it impacts the company's funding and trial progress.